The Bone Health Conversation Nobody Is Having GLP-1 medications should not be framed as directly causing bone loss
Patients with a history of pancreatitis, medullary thyroid cancer, or multiple endocrine neoplasia type 2 should never take GLP-1 medications, regardless of inflammatory bowel disease status
Suitable candidates typically include adults with a Body Mass Index (BMI) of 30 kg/m or higher, indicating obesity, or those with a BMI of at least 27 kg/m and weight-related health conditions, such as elevated cholesterol levels, hypertension, or type 2 diabetes
These initial consultations are essential for closely monitoring your progress and making any necessary adjustments to your personalized plan
Ghosh, A., Parida, V
Real-world claim data shows average authorization timelines of 5-14 business days, during which patients remain without medication access